Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Brigade Enterprises Ltd., Deepak Fertilizers and Petrochemicals Corp., Sun Pharmaceutical Industries Ltd. and AstraZeneca ...

In March, the company had received approval from the drug regulator to import and sell sodium zirconium cyclosilicate powder ...

The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

Panelists discuss how the rise of patient awareness around subcutaneous (SubQ) therapies calls for empathetic, evidence-based education, shared decision-making, and seamless system integration to ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Detailed price information for Mustang Bio Inc (MBIO-Q) from The Globe and Mail including charting and trades.